Abstract
Here we describe a 47-year-old postmenopausal woman who had been taking alendronate 70 mg/week for osteoporosis. After two months of alendronate therapy, she developed hepatotoxicity, and no other etiological factors for this besides the alendronate were apparent. After the alendronate therapy was discontinued, the patient’s hepatic enzyme levels slowly returned to normal. Hepatotoxicity due to alendronate therapy is a rare but possible adverse effect.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Peter C, Rodan GA (1999) Preclinical safety profile of alendronate. Int J Clin Pract Suppl 101:3–8
Felsenberg D, Alenfeld F, Bock O, Hammermeister C, Gowan W (1998) Placebo-controlled multicenter study of oral alendronate in postmenopausal osteoporotic women. FOSIT-Study-Group. Fosamax International Trial. Maturitas 31:35–44
Watts N, Freedholm D, Daifotis A (1999) Alendronate: from the laboratory to the patient: the clinical tolerability profile of alendronate. Int J Clin Pract 101:51–61
Eisman JA, Rizzoli R, Roman-Ivorra J, Lipschitz S, Verbruggen N, Gaines KA, Melton ME (2004) Upper gastrointestinal and overall tolerability of alendronate once weekly in patients with osteoporosis: results of a randomized, double-blind, placebo-controlled study. Curr Med Res Opin 20:699–705
Greenspan S, Field-Munves E, Tonino R, Smith M, Petruschke R, Wang L, Yates J, de Papp AE, Palmisano J (2002) Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. Mayo Clin Proc 77:1044–1052
Pols HA, Felsenberg D, Hanley DA, Stepan J, Munoz-Torres M, Wilkin TJ, Qin-sheng G, Galich AM, Vandormael K, Yates AJ, Stych B (1999) Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 9:461–468
Shiraki M, Kushida K, Fukunaga M, Kishimoto H, Taga M, Nakamura T, Kaneda K, Minaguchi H, Inoue T, Morii H, Tomita A, Yamamoto K, Nagata Y, Nakashima M, Orimo H (1999) A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. The Alendronate Phase III Osteoporosis Treatment Research Group. Osteoporos Int 10:183–192
Ferrari AP Jr, Domingues SH (1998) Esophageal ulcer and alendronate. Sao Paulo Med J 116:1882–1884
Nase JB, Suzuki JB (2006) Osteonecrosis of the jaw and oral bisphosphonate treatment. J Am Dent Assoc 137:1115–1119
Maalouf NM, Heller HJ, Odvina CV, Kim PJ, Sakhaee K (2006) Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature. Endocr Pract 12:48–53
Coleman CI, Perkerson KA, Lewis A (2004) Alendronate-induced auditory hallucinations and visual disturbances. Pharmacotherapy 24:799–802
Mayoral W, Lewis JH, Zimmerman H (1999) Drug-induced liver disease. Curr Opin Gastroenterol 15:208–216
Lieverse RJ (1998) Hepatitis after alendronate. Neth J Med 53:271–272
Halabe A, Lifschitz BM, Azuri J (2000) Liver damage due to alendronate. N Engl J Med 343:365–366
de La Serna Higuera C, Perez Villoria A, Rodriguez Gomez S, Martinez Moreno J, Betancourt Gonzalez A, Martin Arribas M (2001) Alendronate-induced hepatocellular lesion Gastroenterol Hepatol 24:244–246
Carrere C, Duval JL, Godard B, De Jaureguiberry JP, Ciribilli JM (2002) Severe acute hepatitis induced by alendronate. Gastroenterol Clin Biol 26:179–180
Acknowledgements
No funds have been received to support this study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yanık, B., Turkay, C. & Atalar, H. Hepatotoxicity induced by alendronate therapy. Osteoporos Int 18, 829–831 (2007). https://doi.org/10.1007/s00198-007-0323-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-007-0323-2